Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists
- PMID: 8806975
- DOI: 10.1016/0895-7061(96)00021-0
Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists
Erratum in
- Am J Hypertens 1997 Apr;10(4 Pt 1):482
Abstract
Medications given once daily may increase compliance for treatment of hypertension, if the drugs have a prolonged duration of action. The time-effect profiles for antihypertensive drugs may not depend entirely on pharmacokinetic measurements (plasma levels). Thus, trough/peak effects on blood pressure should be measured. It has been suggested that trough/peak ratios be greater than 50% for optimal 24-h control of pressure. Because very little information is available for many angiotensin converting enzyme (ACE) inhibitors and calcium antagonists concerning their trough/peak ratios and awaiting prospective comparative trials with adequate methodology, we have analyzed the duration of action of blood pressure lowering during long-term therapy with commercially available ACE inhibitors and calcium antagonists in published studies that used ambulatory blood pressure monitoring. Published studies were searched in scientific databases using relevant key words. Twenty-four ACE inhibitor and 34 calcium antagonist studies with comparable methodologies were selected. The mean trough/ peak ratios were computed after reconstruction of the curve of the magnitude of blood pressure changes against time. The results showed that once daily administration of ACE inhibitors produced on average ratios higher than 50% with fosinopril (64%), ramipril (50% to 63%), and trandolapril (50% to 100%). Other studied ACE inhibitors produced ratios on average equal to [enalapril (40% to 64%), cilazapril (10% to 80%), lisinopril (30% to 70%)] or significantly lower than 50% [captopril (25%), benazepril (40%), perindopril (35%), quinapril (10% to 40%), and moexipril (0% to 9%)]. As for once daily calcium antagonists, amlodipine (50% to 100%), lacidipine (40% to 100%), nifedipine Coat-Core (50% to 69%), nifedipine gastrointestinal therapeutic system (GITS) (60% to 94%), as well as various "slow release" formulations of diltiazem (20% to 80%) and verapamil (45% to 100%) had on average ratios higher than 50% whereas felodipine ER (30% to 45%), various slow release formulations of isradipine (10% to 80%), and nitrendipine (10% to 80%) had ratios lower than 50%. Although this retrospective literature analysis may have some theoretical limitations, it suggests that not all once daily ACE inhibitors and calcium antagonists cause trough/peak ratio superior to 50%. This may have important clinical implications.
Comment in
-
Trough-to-peak ratio of angiotensin converting enzyme inhibitors and calcium antagonists.Am J Hypertens. 1997 May;10(5 Pt 1):580-2. Am J Hypertens. 1997. PMID: 9160773 No abstract available.
-
Comments on the study of Zannad et al. Monitoring to evaluate antihypertensive therapy.Am J Hypertens. 1997 Oct;10(10 Pt 1):1190. doi: 10.1016/s0895-7061(97)90558-6. Am J Hypertens. 1997. PMID: 9370392 No abstract available.
Similar articles
-
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.Clin Pharmacokinet. 2002;41(3):207-24. doi: 10.2165/00003088-200241030-00005. Clin Pharmacokinet. 2002. PMID: 11929321 Review.
-
Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.Can J Cardiol. 1998 May;14(5):682-8. Can J Cardiol. 1998. PMID: 9627524 Clinical Trial.
-
Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors.J Hypertens Suppl. 1994 Nov;12(8):S91-4; discussion S94-5. J Hypertens Suppl. 1994. PMID: 7707164 Review.
-
Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?Drugs. 1993;46 Suppl 2:172-81; discussion 182. doi: 10.2165/00003495-199300462-00027. Drugs. 1993. PMID: 7512472 Review.
-
Clinical pharmacokinetics of vasodilators. Part I.Clin Pharmacokinet. 1998 Jun;34(6):457-82. doi: 10.2165/00003088-199834060-00003. Clin Pharmacokinet. 1998. PMID: 9646008 Review.
Cited by
-
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.Clin Pharmacokinet. 2002;41(3):207-24. doi: 10.2165/00003088-200241030-00005. Clin Pharmacokinet. 2002. PMID: 11929321 Review.
-
Once- Versus Twice-Daily Angiotensin-Converting Enzyme Inhibitors for Blood Pressure Control in Adult Patients With Hypertension.Cureus. 2021 Aug 20;13(8):e17331. doi: 10.7759/cureus.17331. eCollection 2021 Aug. Cureus. 2021. PMID: 34567875 Free PMC article. Review.
-
Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.PLoS One. 2020 Dec 3;15(12):e0243371. doi: 10.1371/journal.pone.0243371. eCollection 2020. PLoS One. 2020. PMID: 33270787 Free PMC article.
-
Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.Drugs. 2010 Oct 22;70(15):2011-49. doi: 10.2165/11204360-000000000-00000. Drugs. 2010. PMID: 20883056 Review.
-
[Differentiation and evaluation of calcium antagonists in therapy of arterial hypertension].Internist (Berl). 2003 Apr;44(4):483-90. doi: 10.1007/s00108-003-0870-3. Internist (Berl). 2003. PMID: 12914406 German. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous